Business
Theralase(R) Demonstrates Efficacy of Rutherrin(R) in Destruction of Non-Hodgkin's Lymphoma
Rutherrin(R), when combined with a common diabetic drug and radiation, was able to effectively de...
About this update from Theralase Technologies Inc.
[{"type":"text","content":"Theralase(R) Demonstrates Efficacy of Rutherrin(R) in Destruction of Non-Hodgkin's LymphomaRutherrin(R), when combined with a common diabetic drug and radiation, was able to effectively destroy Non-Hodgkin's Lymphoma in an animal model.Toronto, Ontario--(Newsfile Corp. - February 25, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (\"Theralase®\" or the \"Company\"), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that Rutherrin® has demonstrated an ability to destroy Non-Hodgkin's Lymphoma (\"NHL\") in an animal model, when combined with Metformin (a common diabetes drug) and radiation.Rutherrin® is the Company's lead compound currently under development for Intra Venous (\"IV\") administration to treat numerous cancers; including: brain, lung, pancreatic and muscle invasive bladder cancer.NHL is a cancer that starts in lymphocytes, a type of white blood cell, located in the bone marrow, blood and lymphatic system. Lymphocytes help protect the body against germs and abnormal cells; including, cancer cells.1NHL ranked as the 5th to 9th most common cancer in most countries globally, with an estimated 544,000 new cancer cases and 260,000 cancer deaths in 2020.2 The global market for NHL is estimated to reach $USD 16.5 billion by 2031.3 In the latest research, mice were inoculated with A20 mouse lymphoma cells subcutaneously (\"SQ\") on day 0. At day 10, tumours reached 3 to 5 mm in size. To simulate proposed human treatments, mice were treated for 3 weeks with:Rutherrin® IV (3 times per week)Metformin intraperitoneally (daily) Radiation (5 times per week)All treatments were stopped after 3 weeks of treatment and tumour volumes were assessed.The results support the use of Rutherrin®, activated by both Metformin and radiation, in the effective treatment of NHL in a SQ mouse model.Figure 1: Treatment without RadiationTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/2786/242318_00bf067ea4f9394d_001full.jpgFigure 2: Treatment with RadiationTo view an enhanced version of this graphic, please visit:https://ima...